Maiva Pharma Secures Rs 1,000 Crore Investment from Morgan Stanley PE and India Life Sciences Fund
Maiva Pharma, a Bengaluru-based injectable contract manufacturer, has secured Rs 1,000 crore from Morgan Stanley Private Equity Asia and India Life Sciences Fund for a controlling stake. The funds will finance a new manufacturing facility that will expand Maiva's capabilities in sterile dosage forms and injectables. This is the company's first private equity fundraise. The investment is expected to strengthen Maiva's growth in the injectables CDMO market.
- Country:
- India
Maiva Pharma on Thursday said it has raised Rs 1,000 crore from Morgan Stanley Private Equity Asia and India Life Sciences Fund.
The transaction includes both primary and secondary funding, the Bengaluru-based pure play injectables contract development and manufacturing organisation said.
The two investors have jointly acquired a controlling stake from existing investors and also infused primary capital into the company, an official statement said, without disclosing the stakes picked up.
This is Maiva's first private equity fundraise and the proceeds will be used to set up a new manufacturing facility near Karnataka's Hosur with capabilities in sterile dosage forms, including pre-filled syringes, bags, oncology, and hormonal injectables.
It already has a facility in Hosur approved by the USFDA and other regulators that manufacture vials.
''This fundraise will be used to add more vial, lyophilisation, and suspension capacity and introduce new manufacturing capabilities such as prefilled syringes, cartridges and bags,'' its Managing Director and Chief Executive Bhaskar Krishna said.
Morgan Stanley PE Asia's Managing Director and Co-Head Nirav Mehta said the injectables CDMO market is poised for strong growth and the company is well-positioned to gain from it.
Complex injectables development and manufacturing capability, strong compliance and regulatory standards, along with transparency and leadership, differentiate Maiva from its competitors, Sumit Gupta, managing director of Invascent, which acts as the investment manager to India Life Sciences Fund IV, said.
Avendus acted as the exclusive financial advisor to Maiva and its shareholders on the deal, the statement said.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
"He wants to make his son the CM...": Expelled Karnataka BJP leader Eshwarappa accuses Yediyurappa of sidelining Hindu leaders
Amit Shah alleges Congress received SDPI support in Karnataka, followed by Bengaluru bomb blast
SDPI played crucial role in Congress' Karnataka victory, claims Amit Shah
Heatwave conditions to prevail in several districts in Karnataka: IMD
Molestation, Abduction Case: MLA Revanna Served Second Notice, Confirms Karnataka HM